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Introduction {#jah31671-sec-0004}
============

A large body of epidemiological evidence has shown consistent associations between exposure to ambient air pollution and risk of cardiovascular disease (CVD),[1](#jah31671-bib-0001){ref-type="ref"} with the majority of studies conducted in population‐based cohorts from the general population. These studies reported associations of various CVD‐related phenotypes, including coronary artery disease (CAD), myocardial infarction (MI), and stroke, with both short‐ and long‐term exposure to pollutants such as fine particulate matter with aerodynamic diameter ≤2.5 μm (PM~2.5~), ozone, and nitrogen dioxide (NO~2~).[1](#jah31671-bib-0001){ref-type="ref"}, [2](#jah31671-bib-0002){ref-type="ref"}, [3](#jah31671-bib-0003){ref-type="ref"} Although experimental data from animal models also support the notion that ambient air pollution promotes the development of atherosclerosis and related risk factors,[4](#jah31671-bib-0004){ref-type="ref"}, [5](#jah31671-bib-0005){ref-type="ref"}, [6](#jah31671-bib-0006){ref-type="ref"}, [7](#jah31671-bib-0007){ref-type="ref"} few studies have investigated the relationship between ambient air pollution exposure and the extent of coronary atherosclerosis in humans because this phenotype usually requires invasive procedures such as coronary angiography. Moreover, the underlying biological processes for these associations are not fully understood, although multiple plausible mechanisms have been proposed, including systemic inflammation, oxidative stress, endothelial dysfunction, thrombosis, and arrhythmia.[8](#jah31671-bib-0008){ref-type="ref"}, [9](#jah31671-bib-0009){ref-type="ref"}, [10](#jah31671-bib-0010){ref-type="ref"}

Despite previous evidence linking air pollution with CVD, many questions remain to be answered, particularly with respect to clinical management of highly susceptible populations. Patients with CAD, for example, still have a 50% increased risk of incident events even in the contemporary era of high‐potency statin therapy.[11](#jah31671-bib-0011){ref-type="ref"} In this regard, it is not known whether prolonged exposure to air pollution increases risk of incident clinical events and whether the increased risk depends on the presence or extent of coronary atherosclerosis or is attenuated by statin therapy. To address these gaps in knowledge that may inform future prevention strategies, we investigated whether exposure to ambient air pollutants, such as PM~2.5~ and NO~2~, was associated with the degree of coronary stenosis and the prospective risk of MI, stroke, or all‐cause mortality in a cohort of patients undergoing elective diagnostic coronary angiography.

Methods {#jah31671-sec-0005}
=======

Study Population {#jah31671-sec-0006}
----------------

The Cleveland Clinic GeneBank study is a single‐site sample repository generated from consecutive patients undergoing elective diagnostic coronary angiography or elective cardiac computed tomographic angiography with extensive clinical and laboratory characterization and longitudinal observation. Participant recruitment occurred between 2001 and 2007, and all patients provided written informed consent prior to being enrolled. Ethnicity was self‐reported, and information regarding demographics, medical history, and medication use was obtained by patient interviews and confirmed by chart reviews at baseline enrollment. Assessment of functional capacity, as a measure of physical activity, was estimated at enrollment based on the self‐administered Duke Activity Status Index questionnaire.[12](#jah31671-bib-0012){ref-type="ref"} All clinical outcome data were verified by source documentation. At baseline, CAD was defined as adjudicated diagnoses of stable or unstable angina, MI (adjudicated definition based on defined electrocardiographic changes or elevated cardiac enzymes), angiographic evidence of ≥50% stenosis in ≥1 major epicardial vessel, and/or a history of known CAD (documented MI, CAD, or history of revascularization). Coronary atherosclerosis severity at baseline was defined as the number of major epicardial vessels with ≥50% stenosis. All quantitative determinations of coronary stenosis were adjudicated by a cardiologist blinded to participant identity. Prospective cardiovascular risk was assessed by the incidence of all‐cause mortality or nonfatal MI or stroke during 3 years of follow‐up from the time of enrollment. Participants were contacted annually either directly in person, by telephone follow‐up, or by other means. In the case of a participant being deceased, a preidentified and pre--agreed upon proxy was contacted. Nonfatal events were defined as MI or stroke in patients who survived at least 48 hours following the onset of symptoms, and all adjudicated outcomes were confirmed using source documentation. The GeneBank Study has been used previously for discovery and replication of novel genes and risk factors for CAD.[13](#jah31671-bib-0013){ref-type="ref"}, [14](#jah31671-bib-0014){ref-type="ref"}, [15](#jah31671-bib-0015){ref-type="ref"}, [16](#jah31671-bib-0016){ref-type="ref"}, [17](#jah31671-bib-0017){ref-type="ref"}, [18](#jah31671-bib-0018){ref-type="ref"}, [19](#jah31671-bib-0019){ref-type="ref"}, [20](#jah31671-bib-0020){ref-type="ref"} The present study was approved by the institutional review boards of the Cleveland Clinic and the University of Southern California Keck School of Medicine.

Clinical Laboratory Measurements {#jah31671-sec-0007}
--------------------------------

Samples were collected from overnight fasted participants on the day of elective cardiac catheterization. Plasma aliquots were isolated from whole blood collected into EDTA tubes, maintained at 0 to 4°C immediately following phlebotomy, processed within 4 hours of blood draw, and stored at −80°C until analysis. Plasma levels of total cholesterol, low‐ and high‐density lipoprotein cholesterol, triglycerides, and high‐sensitivity C‐reactive protein were measured on the Architect platform (Abbott Diagnostics).

Air Pollution Exposure Assessment {#jah31671-sec-0008}
---------------------------------

Daily concentrations of PM~2.5~ and NO~2~ in the United States from 1998 through 2010 were downloaded from the US Environmental Protection Agency\'s (EPA) Air Quality System (AQS) database (<https://www.epa.gov/aqs>). This national database contains hourly and daily outdoor air pollution concentration data back to the late 1970s, and the network has remained fairly stable since 2000 for PM~2.5~ and NO~2~. Data for PM~2.5~ and NO~2~ were primarily limited to those collected with Federal Reference Method samplers and Federal Equivalent Method monitors. Non--Federal Reference Method PM~2.5~ and NO~2~ data were used only when Federal Reference or Equivalent Method measurement data were not available for a location. Because ozone was not routinely monitored across the year in many locations, it was not included in this study. Automated quality control checks on the concentration ranges and persistence were applied to the AQS data. Because the national air‐monitoring networks began measuring PM~2.5~ and NO~2~ in 1999, few data exist prior to that date. The hourly PM~2.5~ and NO~2~ data were averaged into standard daily exposure metrics, and monthly averages were calculated from the daily average pollutant data. A 75% data completeness criterion was used in determining monthly averages. Because the historical daily PM~2.5~ measurements were often made once every third or sixth day rather than daily, the completeness criterion was applied based on the expected completeness for a 1‐in‐6‐day sampling schedule. Monthly air‐quality exposure values were spatially interpolated from the air‐quality monitoring locations of the residential ZIP code coordinates (based on geographic centroid) of each participant at the time of enrollment into the GeneBank study. The station‐specific monthly air‐quality data were spatially interpolated using inverse distance‐squared weighting. The data from up to 4 air‐quality measurement stations were included in each interpolation. Because of the regional nature of PM~2.5~ and NO~2~ concentrations, a maximum interpolation radius of 50 km was used; however, when a residence was located within 5 km of ≥1 station with valid observations, the interpolation was based solely on the concentrations from the stations within 5 km. The same 75% completeness criteria were applied to the estimates of average exposures for each exposure period. Estimated levels of PM~2.5~ and NO~2~ were based on 46 and 4 monitoring sites, respectively.

Land Use Assignment {#jah31671-sec-0009}
-------------------

The National Land Cover Database (NLCD) for 2011 was used to assess the extent of industrial development near each participant\'s reported residence.[21](#jah31671-bib-0021){ref-type="ref"} The NLCD provides many categories of land cover at the native 30‐m resolution of the Landsat Thematic Mapper. Specifically, we used the land cover class (class 24: developed, high intensity) that combines commercial, industrial, high‐density residential, and transportation land use and is characterized by 80% to 100% impervious surfaces. The percentage of industrial‐like land cover in the postal ZIP code area, defined by the 2010 5‐digit ZIP code boundaries, of each participant\'s residence was computed in a geographic information system (ArcGIS version 10.3; Esri). This measure was significantly correlated with levels before and after enrollment of PM~2.5~ (*r*=0.25 and *r*=0.29, respectively; *P*\<0.0001) and NO~2~ (*r*=0.22 and *r*=0.20, respectively; *P*\<0.0001).

Statistical Analyses {#jah31671-sec-0010}
--------------------

Primary outcomes included the degree of coronary atherosclerosis severity at baseline (0, 1--2, or ≥3 epicardial vessels with ≥50% stenosis) and prospective incident events (nonfatal MI, stroke, all‐cause mortality) over 3 years of follow‐up. Participants who experienced an event within 14 days of enrollment were excluded from the analyses to omit acute events during the initial baseline period. Air pollution variables for each participant included estimated levels of exposure to PM~2.5~ (in μg/m^3^) and NO~2~ (in parts per billion) during the 36 months prior to baseline enrollment and the 36 months after enrollment for cross‐sectional and prospective analyses, respectively. Multinomial logistic regression was applied to evaluate the effect of air pollution on coronary atherosclerosis severity among participants with CAD at baseline. Cox proportional hazards models were used to estimate the effect of ambient air pollution on prospective events among all participants and in a subset with CAD at baseline. To test for confounding after adjustment for a priori covariates (age, sex, smoking, and education), we performed sensitivity analyses with the following variables: obesity (body mass index \<30 versus ≥30), statin therapy use (yes or no), high‐sensitivity C‐reactive protein, and coronary atherosclerosis severity (0, 1--2 or ≥3 epicardial vessels with ≥50% stenosis). In addition, we tested whether cardiovascular risk factors modified the effects of air pollution on CAD outcomes by further adjusting for Framingham Adult Treatment Panel III (ATP III) risk score (including total and high‐ and low‐density lipoprotein cholesterol levels, presence of atherosclerosis, family history of premature coronary heart disease, smoking, hypertension, diabetes mellitus, and age). None of the above potential covariates changed the estimates considerably (\>10%); therefore, the final model included the a priori selected covariates of age, sex, current smoking (yes or no), and education level (college or higher, high school, less than high school) as adjusting variables. To assess potential residual confounding, physical activity and commercial/industrial land use were included in the models to test their influence on the effect estimates. Multipollutant models were further adjusted for the other respective copollutant. Additional analyses for association of PM~2.5~ levels with incident MI were performed after stratifying by the presence of coronary atherosclerosis (≥1 epicardial vessel with ≥50% stenosis) and/or statin therapy use and by median age (≥64 years), sex, education level, current smoking, or obesity (body mass index ≥30). Adjusted hazard ratios or odds ratios with 95% CIs are reported with 2‐sided *P* values. Interaction *P* values were obtained from likelihood ratio tests. All analyses were performed using SAS 9.3 (SAS Institute Inc).

Results {#jah31671-sec-0011}
=======

Clinical Characteristics of GeneBank Participants {#jah31671-sec-0012}
-------------------------------------------------

The clinical characteristics of the GeneBank participants in this study are described in Table [1](#jah31671-tbl-0001){ref-type="table-wrap"} and Table S1. To avoid the potential for referral bias, only those participants whose residential ZIP codes were reported as being in Ohio (n=6575) were included. As expected for a patient population undergoing elective coronary angiography for clinical evaluation, the majority of participants at enrollment were male, had prevalent CAD, and were using statin therapy. In addition, a significant fraction of participants were obese or had diabetes, and most had attained at least a high school level of education (Table [1](#jah31671-tbl-0001){ref-type="table-wrap"} and Table S1).

###### 

Clinical Characteristics of GeneBank Participants Residing in Ohio

  Trait                                                                               n=6575
  ----------------------------------------------------------------------------------- ----------------
  Age, y                                                                              64±11
  Male                                                                                4462 (68)
  CAD at baseline                                                                     4904 (77)
  Number of epicardial vessels with stenosis ≥50%                                     
  0 vessels                                                                           1961 (30)
  1 or 2 vessels                                                                      2503 (38)
  ≥3 vessels                                                                          2111 (32)
  MI                                                                                  288 (4)
  Stroke                                                                              127 (2)
  All‐cause mortality                                                                 590 (9)
  CRP, mg/L[a](#jah31671-note-0003){ref-type="fn"}                                    2.6 (1.1--6.3)
  Total cholesterol, mg/dL                                                            171±41
  HDL cholesterol, mg/dL                                                              40±13
  LDL cholesterol, mg/dL                                                              100±34
  Triglycerides, mg/dL                                                                155±110
  Framingham ATP III risk score[b](#jah31671-note-0004){ref-type="fn"}                
  Male                                                                                7.9±3.0
  Female                                                                              10.9±4.8
  BMI category, kg/m^2^                                                               
  \<30                                                                                3848 (59)
  ≥30                                                                                 2727 (41)
  Diabetes mellitus                                                                   2485 (38)
  Current smokers                                                                     916 (14)
  Using statin therapy                                                                3857 (59)
  Education[c](#jah31671-note-0005){ref-type="fn"}                                    
  College or higher                                                                   2812 (43)
  High school                                                                         2809 (43)
  Less than high school                                                               951 (15)
  DASI score[d](#jah31671-note-0006){ref-type="fn"}                                   37.7±15.9
  Commercial/industrial land use development[e](#jah31671-note-0007){ref-type="fn"}   3.2±4.0

Data are shown as mean±SD or numbers of participants (%). ATP III indicates Adult Treatment Panel III; BMI, body mass index; CAD, coronary artery disease; CRP, high sensitivity C‐reactive protein; DASI, Duke Activity Status Index; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; MI, myocardial infarction.

CRP levels were available for 3572 participants and are shown as median (IQR).

Framingham ATP III risk scores were available for 6395 participants. Sex‐specific risk scores were calculated according to ATP III guidelines using total and LDL‐ and HDL cholesterol levels, presence of atherosclerosis, smoking status, hypertension, diabetes mellitus, and age.

≥College indicates 2--4 years of college or postgraduate education.

DASI (measure of physical activity) was available for 5509 participants.

Commercial/industrial land development indicates the percentage of commercial/industrial land use in current ZIP code boundaries.

Description of Air Pollutants {#jah31671-sec-0013}
-----------------------------

Air pollution variables included average estimated daily exposure levels of PM~2.5~ and NO~2~ during the 36 months prior to enrollment and the 36 months after enrollment for cross‐sectional and prospective analyses, respectively. As shown in Figure [1](#jah31671-fig-0001){ref-type="fig"}, GeneBank participants who reported their residential ZIP codes as being located in Ohio were clustered in metropolitan regions, particularly in the area surrounding Cleveland. Estimated exposure levels for PM~2.5~ in the 36 months before and after enrollment were available for ≈6100 Ohio residents and ranged from 10 to 21 μg/m^3^, whereas NO~2~ levels were available for ≈4600 participants and ranged from 5 to 23 parts per billion (Figure [2](#jah31671-fig-0002){ref-type="fig"}). Exposure levels of each pollutant during the 36 months before and after enrollment were strongly correlated with each other, with comparable means, whereas PM~2.5~ and NO~2~ levels were only weakly correlated with each other regardless of exposure period (Figure S1). Based on data from the EPA, PM~2.5~ levels in Ohio during the pre‐ and postenrollment periods (1998--2010) were comparable to US national and regional trends, whereas NO~2~ levels were lower. This may have been caused by the small number of monitoring sites for NO~2~, which led to fewer participants receiving assignments for this pollutant compared with PM~2.5~ and limiting exposure contrast.

![Distribution of residential ZIP codes in the GeneBank cohort. The geographic locations of the residential ZIP codes reported by GeneBank participants residing in Ohio are denoted by red dots. Most participants were clustered in metropolitan regions, particularly the surrounding Cleveland area, although there are also relatively high‐density clusters in the northeast, central, and southwest regions of Ohio.](JAH3-5-e003947-g001){#jah31671-fig-0001}

![Distribution of ambient air pollution exposure levels. The distributions of PM ~2.5~ (blue) and NO ~2~ (gray) levels in the GeneBank cohort during the 36 months before and after enrollment are shown. For each time period, PM ~2.5~ and NO ~2~ levels (mean±SD) were estimated for ≈6100 and ≈4600 participants, respectively. max indicates maximum; min, minimum; NO~2~, nitrogen dioxide; PM~2.5~, fine particulate matter \<2.5 μm in diameter; ppb, parts per billion.](JAH3-5-e003947-g002){#jah31671-fig-0002}

Effect of Air Pollution Exposure on Severity of Coronary Atherosclerosis {#jah31671-sec-0014}
------------------------------------------------------------------------

We determined the association of air pollution levels before study entry with the extent of coronary atherosclerosis among patients with CAD, defined based on angiographic evidence at baseline or a positive history of CAD. After adjustment for age, sex, education level, and smoking, a 2‐SD (2.2‐μg/m^3^) increase in exposure to PM~2.5~ over the 36 months preceding enrollment was associated with significantly increased likelihood (odds ratio 1.43, 95% CI 1.11--1.83; *P*=0.005) of having mild coronary disease, defined as 1 to 2 vessels with ≥50% stenosis, compared with patients with a history of CAD but no vessels with ≥50% stenosis at baseline (Table [2](#jah31671-tbl-0002){ref-type="table-wrap"}). The association of PM~2.5~ with severe coronary atherosclerosis, defined as ≥3 vessels with ≥50% stenosis, was even more pronounced (odds ratio 1.63, 95% CI 1.26--2.11; *P*\<0.001) (Table [2](#jah31671-tbl-0002){ref-type="table-wrap"}). A test of heterogeneity demonstrated that the effect of PM~2.5~ on severe coronary atherosclerosis was significantly different from the effect on mild disease (heterogeneity *P*=0.03) (Table [2](#jah31671-tbl-0002){ref-type="table-wrap"}). Additional adjustment for the Framingham ATP III risk score, which captures several other CVD risk factors, did not appreciably change the effect estimates (Table [2](#jah31671-tbl-0002){ref-type="table-wrap"}). The magnitude and significance of the association of PM~2.5~ with the extent of coronary atherosclerosis were also not markedly affected after further adjustment for additional potential covariates (Table S2). In comparison, increased NO~2~ levels (2 SD; 4.1 parts per billion) were not associated with the likelihood of having mild or severe atherosclerotic disease (Table [3](#jah31671-tbl-0003){ref-type="table-wrap"}).

###### 

Association of PM~2.5~ Levels With Coronary Atherosclerosis Severity Among Participants With CAD at Baseline

  Outcome          n (Rate)      OR (95% CI)         *P* Value[a](#jah31671-note-0009){ref-type="fn"}   *P* Value[b](#jah31671-note-0010){ref-type="fn"}   
  ---------------- ------------- ------------------- -------------------------------------------------- -------------------------------------------------- ------
  Model 1                                                                                                                                                  
  0 vessels        271 (0.06)    1.00                1.00                                               ---                                                ---
  1 or 2 vessels   2324 (0.51)   1.17 (1.05--1.31)   1.43 (1.11--1.83)                                  0.005                                              ---
  ≥3 vessels       1923 (0.43)   1.24 (1.11--1.40)   1.63 (1.26--2.11)                                  \<0.001                                            0.03
  Model 2                                                                                                                                                  
  0 vessels        256 (0.06)    1.00                1.00                                               ---                                                ---
  1 or 2 vessels   2283 (0.52)   1.15 (1.03--1.29)   1.37 (1.06--1.77)                                  0.02                                               ---
  ≥3 vessels       1887 (0.43)   1.22 (1.09--1.37)   1.56 (1.20--2.04)                                  \<0.001                                            0.04

ORs, 95% CIs, and *P* values were obtained using multinomial logistic regression with 36‐month prior‐to‐baseline exposure levels. Model 1 was adjusted for age, sex, education level (college or higher, high school, less than high school), and current smoking. Model 2 included model 1 plus adjustment for Framingham Adult Treatment Panel III risk score. CAD indicates coronary artery disease; OR, odds ratio; PM~2.5~, fine particulate matter \<2.5 μm in diameter.

Multinomial test of effects of PM~2.5~ levels on coronary atherosclerosis severity (defined as 1--2 or ≥3 epicardial vessels with ≥50% stenosis) compared with the reference group (no epicardial vessels with ≥50% stenosis).

Test of heterogeneity for the effect of PM~2.5~ levels on coronary atherosclerosis severity: 1‐ or 2‐vessel disease vs ≥3‐vessel disease.

###### 

Association of NO~2~ Levels With Coronary Atherosclerosis Severity Among Participants With CAD at Baseline

  Outcome          n (Rate)      OR (95% CI)         *P* Value[a](#jah31671-note-0012){ref-type="fn"}   *P* Value[b](#jah31671-note-0013){ref-type="fn"}   
  ---------------- ------------- ------------------- -------------------------------------------------- -------------------------------------------------- ------
  Model 1                                                                                                                                                  
  0 vessels        211 (0.06)    1.00                1.00                                               ---                                                ---
  1 or 2 vessels   1795 (0.52)   1.00 (0.92--1.09)   1.01 (0.75--1.35)                                  0.95                                               ---
  ≥3 vessels       1471 (0.42)   0.98 (0.90--1.06)   0.92 (0.68--1.24)                                  0.58                                               0.20
  Model 2                                                                                                                                                  
  0 vessels        200 (0.06)    1.00                1.00                                               ---                                                ---
  1 or 2 vessels   1763 (0.52)   1.00 (0.92--1.09)   1.00 (0.74--1.34)                                  0.98                                               ---
  ≥3 vessels       1441 (0.42)   0.97 (0.89--1.06)   0.90 (0.67--1.23)                                  0.52                                               0.19

ORs, 95% CIs, and *P* values were obtained using multinomial logistic regression with 36‐month prior‐to‐baseline exposure levels. Model 1 was adjusted for age, sex, education level (college or higher, high school, less than high school), and current smoking. Model 2 included model 1 plus adjustment for Framingham Adult Treatment Panel III risk score. CAD indicates coronary artery disease; NO~2~, nitrogen dioxide; OR, odds ratio; ppb, parts per billion.

Multinomial test of effects of NO~2~ levels on coronary atherosclerosis severity (defined as 1--2 or ≥3 epicardial vessels with ≥50% stenosis) compared with the reference group (no epicardial vessels with ≥50% stenosis).

Test of heterogeneity for the effect of NO~2~ levels on coronary atherosclerosis severity: 1‐ or 2‐vessel disease vs ≥3‐vessel disease.

Effect of Air Pollutants on Incident Clinical Events {#jah31671-sec-0015}
----------------------------------------------------

We next investigated whether air pollution levels were associated with prospective risk of incident MI, stroke, and all‐cause mortality among all GeneBank participants. A 2‐SD increase in PM~2.5~ levels over 36 months of follow‐up after angiographic evaluation was associated with significantly increased risk of MI (hazard ratio 1.33, 95% CI 1.02--1.73; *P*=0.03) (Table [4](#jah31671-tbl-0004){ref-type="table-wrap"}). The effect estimates for the association of PM~2.5~ and MI risk were not substantially changed in models that adjusted for Framingham ATP III risk score (Table [4](#jah31671-tbl-0004){ref-type="table-wrap"}) and other potential covariates (Table S3) or in a multipollutant model adjusting for NO~2~ levels (Table S4). Restricting these analyses to only patients with angiographically determined CAD at baseline yielded similar effect estimates (Table S3). To address the potential for referral bias further, we also carried out an analysis that included only participants from the greater Cleveland metropolitan area (n=3437). The effect estimate obtained from this subanalysis with ≈2400 fewer participants (hazard ratio 1.12; 95% CI 0.96--1.30; *P*=0.15) was comparable and directionally consistent with the analysis that included all Ohio residents (Table [4](#jah31671-tbl-0004){ref-type="table-wrap"}). By comparison, there were no associations between PM~2.5~ or NO~2~ levels with risk of all‐cause mortality (Tables [4](#jah31671-tbl-0004){ref-type="table-wrap"} and [5](#jah31671-tbl-0005){ref-type="table-wrap"}), whereas a 2‐SD increase in NO~2~ levels was associated with elevated risk of stroke (hazard ratio 1.72, 95% CI 1.03--2.87; *P*=0.04) (Table [5](#jah31671-tbl-0005){ref-type="table-wrap"}); however, this association was no longer significant after adjustment for Framingham ATP III risk score (Table [5](#jah31671-tbl-0005){ref-type="table-wrap"}). It is possible that the lack or attenuation of significance in some of these analyses may have been due to reduced sample size. There were, for example, fewer numbers of participants for whom NO~2~ levels or complete data on the full set of covariates were available (Tables S3 and S4).

###### 

Association of PM~2.5~ Levels With Incident Clinical Events Over 3 Years of Follow‐up

  Outcome               n (Rate)      HR (95% CI)         *P* Value           
  --------------------- ------------- ------------------- ------------------- ------
  Model 1                                                                     
  MI                    5854 (0.04)   1.14 (1.01--1.28)   1.33 (1.02--1.73)   0.03
  Stroke                5875 (0.02)   1.07 (0.89--1.27)   1.15 (0.78--1.69)   0.48
  All‐cause mortality   5854 (0.08)   1.08 (0.99--1.18)   1.18 (0.98--1.43)   0.08
  Model 2                                                                     
  MI                    5696 (0.04)   1.14 (1.01--1.28)   1.32 (1.02--1.17)   0.04
  Stroke                5715 (0.02)   1.03 (0.86--1.23)   1.07 (0.73--1.59)   0.72
  All‐cause mortality   5696 (0.07)   1.07 (0.98--1.17)   1.16 (0.96--1.41)   0.13

HRs, 95% CIs, and *P* values were obtained using Cox proportional hazards models with 36‐month postbaseline exposure levels. Model 1 was adjusted for age, sex, education level (college or higher, high school, less than high school), and current smoking. Model 2 includes model 1 plus adjustment for Framingham Adult Treatment Panel III risk score. HR indicates hazard ratio; MI, myocardial infarction; PM~2.5~, fine particulate matter \<2.5 μm in diameter

###### 

Association of NO~2~ Levels With Incident Clinical Events Over 3 Years of Follow‐up

  Outcome               n (Rate)      HR (95% CI)         *P* Value           
  --------------------- ------------- ------------------- ------------------- ------
  Model 1                                                                     
  MI                    4490 (0.04)   0.99 (0.92--1.06)   0.94 (0.70--1.26)   0.68
  Stroke                4504 (0.02)   1.14 (1.01--1.30)   1.72 (1.03--2.87)   0.04
  All‐cause mortality   4489 (0.08)   1.00 (0.95--1.06)   1.00 (0.81--1.25)   0.98
  Model 2                                                                     
  MI                    4364 (0.04)   0.98 (0.91--1.05)   0.91 (0.68--1.21)   0.51
  Stroke                4377 (0.02)   1.12 (0.98--1.27)   1.56 (0.93--2.61)   0.09
  All‐cause mortality   4363 (0.08)   1.00 (0.94--1.05)   0.99 (0.79--1.23)   0.92

HRs, 95% CIs, and *P* values were obtained using Cox proportional hazards models with 36‐month postbaseline exposure levels. Model 1 was adjusted for age, sex, education level (college or higher, high school, less than high school), and current smoking. Model 2 included model 1 plus adjustment for Framingham Adult Treatment Panel III risk score. HR indicates hazard ratio; MI, myocardial infarction; NO~2~, nitrogen dioxide; ppb, parts per billion.

Effect of PM~2.5~ on Incident MI Stratified by the Presence of Coronary Atherosclerosis at Baseline and/or by Statin Therapy {#jah31671-sec-0016}
----------------------------------------------------------------------------------------------------------------------------

We next performed stratified analyses and formal tests of interaction to determine whether the effect of PM~2.5~ on incident MI was modulated by coronary atherosclerosis at baseline or by the use of statin therapy. Stratifying the analyses by participants who had coronary atherosclerosis at baseline, who used statin medications, or both did not reveal statistical evidence that the effects of PM~2.5~ on MI risk were modulated by these factors (Table S5). There was also no significant statistical evidence that risk of MI was modulated by 3‐way interactions among PM~2.5~, coronary atherosclerosis, and statin therapy use (3‐way interaction *P*=0.33). Last, we investigated whether any of the effects of PM~2.5~ on risk of MI were modified by a priori covariates and performed analyses stratified by median age, sex, education level, smoking, coronary atherosclerosis severity, and obesity (body mass index ≥30), which also included formal tests of interaction. There were no significant effect modifications among these covariates, PM~2.5~, and risk of MI (Table S6).

Discussion {#jah31671-sec-0017}
==========

In the present study, we evaluated the effects of prolonged exposure to ambient air pollution on prevalent and incident risk of adverse clinical events in residents of Ohio who had undergone elective cardiac evaluation at the Cleveland Clinic. Our results demonstrated that a 2‐SD increase in exposure to PM~2.5~ levels during the 36 months preceding enrollment was associated with 43% to 63% increased likelihood of having angiographically determined coronary atherosclerosis at study entry. The effect estimates for these associations were fairly robust with adjustment for various covariates and potential confounders, such as Framingham ATP III risk score, obesity, smoking, physical activity, and land use development. Our results further demonstrated that the effect of PM~2.5~ significantly differed as a function of coronary atherosclerosis severity among patients with a history of CAD or documented angiographic evidence of CAD at enrollment. These observations are consistent with cross‐sectional associations between PM~2.5~ and subclinical atherosclerosis.[22](#jah31671-bib-0022){ref-type="ref"}, [23](#jah31671-bib-0023){ref-type="ref"}, [24](#jah31671-bib-0024){ref-type="ref"}

Our study also represents one of the first analyses with ambient air pollution exposure and incident adverse clinical events in participants undergoing elective cardiac evaluation by angiography. In this highly susceptible patient population, we demonstrated that a 2.2‐μg/m^3^ increase in PM~2.5~ levels during 3 years of follow‐up was specifically associated with increased risk of MI but not stroke or all‐cause mortality. The effect estimates remained comparable when additional covariates, such as NO~2~ levels, physical activity, or commercial/industrial land use, were included in the model, although the significance of the association was slightly attenuated. A possible explanation for this observation may be that the percentage of high‐intensity land development served as a proxy for various unmeasured confounding variables, such as socioeconomic status, even after adjustment for education level. Furthermore, because the percentage of commercial/industrial land use was significantly correlated with PM~2.5~ levels in our data set (*r*=0.29; *P*\<0.0001), its inclusion in the models may have led to overadjustment. Last, the reduced sample sizes in the fully adjusted models could have decreased the power and the level of significance for the association of PM~2.5~ with risk of MI.

Other groups have reported that lipid‐lowering therapies reduce the adverse effects of air pollution on CVD‐related phenotypes.[25](#jah31671-bib-0025){ref-type="ref"}, [26](#jah31671-bib-0026){ref-type="ref"}, [27](#jah31671-bib-0027){ref-type="ref"}, [28](#jah31671-bib-0028){ref-type="ref"} In our patient population, we did not obtain evidence of differential effects of PM~2.5~ on prospective risk of MI when participants were stratified by the use of statins. Information on statin use, however, was available only at baseline, and it is possible that patients had changes in medication use during the follow‐up period that could have modulated the association between PM~2.5~ and incident MI. The association of PM~2.5~ with MI also did not vary as a function of other strata, such as sex, smoking status, education level, obesity, or the presence or severity of coronary atherosclerosis at baseline (≥50% stenosis in ≥1 major epicardial vessel). By comparison, a prospective analysis with \>12 000 participants drawn from the Intermountain Heart Collaborative Study in Utah reported a modest 4.5% increased risk of MI and/or unstable angina for a 10‐μg/m^3^ increase in concurrent‐day PM~2.5~.[29](#jah31671-bib-0029){ref-type="ref"} These participants were also recruited through coronary angiography, but in contrast to our results, the increased risk of an acute coronary event was evident in those with ≥1 severely diseased coronary vessel, defined as ≥70% stenosis. Notably, Pope et al evaluated acute exposure during the few days surrounding the coronary event, whereas we used estimates of exposure over the ensuing 36 months after angiography. Consequently, factors related to assessment and duration of exposure, geographic area, sample size, study populations, and/or disease phenotype definitions could potentially account for some of the differences between our results and those in the Intermountain Heart Collaborative Study.

We also note some limitations of our study. First, despite estimating exposure over 36 months, this time period may not be suitable for examining more long‐term effects of ambient air pollution on adverse clinical events, even in high‐risk populations. Second, the overall event rate for MI, stroke, or all‐cause mortality over 36 months of follow‐up was still relatively low, possibly rendering some of the analyses underpowered for detecting associations or prone to spurious associations. This may have been relevant for the analyses assessing PM~2.5~ exposure and MI risk that were stratified by statin therapy use or presence of coronary atherosclerosis or the more fully adjusted statistical models because fewer participants had complete data for the additional covariates that were included. For similar reasons, the association of NO~2~ with incident events may also have been underpowered because exposure estimates for this pollutant were available in 25% fewer participants than for PM~2.5~. Third, this study included only patients from a single tertiary care center in Cleveland and restricted the analyses to residents of Ohio. We also did not have information on how long patients lived at the reported residential addresses. Consequently, the results may not be generalizable to other geographic locations or populations because the effects of ambient air pollution exposure may vary depending on the sources of pollution, the exposure period, and/or population characteristics. Last, there is the possibility of misclassification in exposure measurements, but these are likely to be nondifferential and would bias the results toward the null.

Conclusions {#jah31671-sec-0018}
===========

We demonstrated that exposure to PM~2.5~ was associated with the extent of CAD severity and increased risk of incident MI among patients undergoing elective cardiac evaluation. These data suggest that reducing exposure to ambient air pollution is an environment‐modifying strategy that may be especially relevant for patients with CAD who are at high risk for MI. The paucity of data on the relationship between ambient air pollution exposure and incident events in patients with CAD merits additional studies with larger study samples to address these questions, which may have important clinical implications for secondary prevention strategies in highly susceptible patients.
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**Table S1.** Clinical Characteristics of GeneBank Participants Residing in Ohio Stratified by Type of Incident Event

**Table S2.** Association of Levels of Fine Particulate Matter \<2.5 μm in Diameter (1 μg/m^3^) With Coronary Atherosclerosis Severity Among Participants With Coronary Artery Disease at Baseline and With Adjustment for Potential Covariates

**Table S3.** Association of Fine Particulate Matter \<2.5 μm in Diameter (1 μg/m^3^) With Myocardial Infarction Over 3 Years of Follow‐up With Adjustment for Potential Covariates

**Table S4.** Multipollutant Model for Association of Levels of Exposure to Fine Particulate Matter \<2.5 μm in Diameter With Myocardial Infarction Over 3 Years of Follow‐up

**Table S5.** Association of Levels of Fine Particulate Matter \<2.5 μm in Diameter (1 μg/m^3^) With Myocardial Infarction Over 3 Years of Follow‐up Stratified by the Presence of Coronary Atherosclerosis at Baseline and Statin Therapy Use

**Table S6.** Association of Levels of Fine Particulate Matter \<2.5 μm in Diameter (1 μg/m^3^) With Myocardial Infarction Over 3 Years of Follow‐up Stratified by Potential Effect Modifiers

**Figure S1.** Correlation of exposure levels 36 months before and after enrollment. Pairwise Pearson correlations between ambient air pollutant levels show that of fine particulate matter \<2.5 μm in diameter (in μg/m^3^) and nitrogen dioxide (in parts per billion) are weakly related regardless of time period, whereas the levels of each pollutant 36 months before and after enrollment are highly correlated.
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